Welcome

The rapid evolution of molecular cardiology, genetics, and targeted therapeutics is reshaping the management of cardiomyopathies and rare cardiovascular diseases. These conditions, though individually uncommon, collectively impose a significant global burden and often require highly specialized, multidisciplinary expertise. As scientific progress accelerates, there is a pressing need for a coordinated international forum where emerging therapeutic strategies can be critically examined, compared, and translated into meaningful clinical advances.

To meet this need, the present workshop will welcome leading experts from around the world, for an interactive meeting dedicated to therapeutic innovation and the future of clinical trial design in this field. Breakthroughs in gene and RNA‑based therapies, precision immunomodulation, disease‑modifying agents, and advanced device technologies are reaching a pivotal moment. Bringing together clinicians, researchers, regulatory authorities, and patient advocates in a collaborative environment will allow participants to explore mechanistic insights, refine trial methodologies, and address challenges such as biomarker development, patient stratification, and long‑term outcome assessment.

Hosting this meeting in Florence — a city historically associated with creativity, exchange, and scientific curiosity — underscores our commitment to fostering open dialogue and global collaboration.

By aligning perspectives across regions and disciplines, the meeting aims to catalyze new partnerships, harmonize research priorities, and ultimately accelerate the delivery of safe, effective, and equitable therapies for patients living with cardiomyopathies and rare cardiovascular diseases.